Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 50.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 504,277 shares of the company’s stock after selling 517,256 shares during the quarter. Jane Street Group LLC owned about 0.34% of Adaptive Biotechnologies worth $2,582,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ADPT. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Adaptive Biotechnologies during the 3rd quarter valued at about $34,000. MQS Management LLC purchased a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $36,000. Rothschild Investment LLC acquired a new stake in Adaptive Biotechnologies during the second quarter worth about $36,000. Finally, Townsquare Capital LLC purchased a new position in Adaptive Biotechnologies during the third quarter worth about $56,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $6.39 on Monday. The company has a market capitalization of $943.03 million, a price-to-earnings ratio of -4.77 and a beta of 1.49. The company’s 50 day simple moving average is $5.50 and its 200-day simple moving average is $4.68. Adaptive Biotechnologies Co. has a 1 year low of $2.28 and a 1 year high of $7.07.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ADPT shares. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler upped their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a report on Monday, November 11th.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.